In a regulatory filing on Friday night, Bristol Myers (BMY) disclosed that its CEO Christopher Boerner bought 2K shares of common stock on February 20th in a total transaction size of $110.1K.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- FDA accepts Bristol Myers’ sBLA for Opdivo plus Yervoy
- Bristol-Myers Squibb: Balancing Growth and Challenges Amidst Market Dynamics – A Hold Recommendation
- Bristol-Myers Squibb: Promising Growth Amidst Legacy Challenges and Policy Headwinds
- Bristol Myers announces OS from Phase 3 CheckMate -816 study
- Bristol Myers announces new five-year results from POETYK PSO trial